Ligand Pharmaceuticals (LGND) Earnings Date, Estimates & Call Transcripts $107.14 +1.13 (+1.07%) (As of 07/26/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateAug. 6After Market ClosesConfirmedActual EPS (May. 7) $3.84 Beat By $3.01 Consensus EPS (May. 7) $0.83 Read Call TranscriptListen to Call Get Ligand Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for LGND and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueLGND Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LGND Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview Ligand Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20241$0.75$0.75$0.75 Q2 20241$0.67$0.67$0.67 Q3 20241$0.80$0.80$0.80 Q4 20241$0.75$0.75$0.75 FY 20244$2.97$2.97$2.97 Q1 20251$0.98$0.98$0.98 Q2 20251$1.01$1.01$1.01 Q3 20251$1.00$1.00$1.00 20253$2.99$2.99$2.99 Q1 20261$1.19$1.19$1.19 LGND Earnings Date and InformationLigand Pharmaceuticals last posted its quarterly earnings results on May 7th, 2024. The biotechnology company reported $3.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.83 by $3.01. The firm had revenue of $30.90 million for the quarter, compared to analysts' expectations of $27.92 million. Its revenue was down 29.8% compared to the same quarter last year. Ligand Pharmaceuticals has generated $5.17 earnings per share over the last year ($5.17 diluted earnings per share) and currently has a price-to-earnings ratio of 20.7. Earnings for Ligand Pharmaceuticals are expected to grow by 29.94% in the coming year, from $3.54 to $4.60 per share. Ligand Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Tuesday, August 6th, 2024. Ligand Pharmaceuticals will be holding an earnings conference call on Tuesday, August 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call.. Read More Ligand Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/6/2024(Confirmed)------- 5/7/2024Q1 2024$0.83$3.84+$3.01($3.15)$27.92 million$30.90 million 2/27/2024Q4 2023$0.24$0.79+$0.55$0.55$24.54 million$28.10 million11/8/2023Q3 2023$0.68$1.02+$0.34$2.16$27.22 million$32.87 million 8/8/2023Q2 2023$0.76$1.42+$0.66$2.07$24.74 million$26.37 million 5/4/2023Q1 2023$0.89$2.28+$1.39$1.59$33.55 million$43.98 million 2/22/2023Q4 2022$1.23$1.36+$0.13$0.52$39.63 million$50.40 million Get the Latest News and Ratings for LGND and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/7/2022Q3 2022$0.09($0.20)($0.29)($0.42)$38.47 million$66.09 million8/8/2022Q2 2022$0.12($0.14)($0.26)($0.23)$39.70 million$57.42 million5/4/2022Q1 2022$0.19$0.15($0.04)$1.21$34.21 million$45.70 million 2/17/2022Q4 2021$0.97$1.34+$0.37$2.98$62.70 million$72.47 million 11/9/2021Q3 2021$0.61$1.58+$0.97$1.56$60.46 million$64.84 million 7/29/2021Q2 2021$1.15$1.63+$0.48$0.53$73.32 million$84.68 million 5/2/2021Q1 2021$1.13$1.41+$0.28$1.01$63.00 million$55.10 million 2/3/2021Q4 2020$0.99$1.62+$0.63$2.05$53.94 million$69.90 million 10/30/2020Q3 2020$0.98$1.04+$0.06$1.84$45.09 million$41.90 million 8/3/2020Q2 2020$0.76$1.00+$0.24($0.02)$29.96 million$41.40 million 5/6/2020Q1 2020$0.66$0.89+$0.23$2.70$26.70 million$33.16 million 2/6/2020Q4 2019$0.64$0.71+$0.07$1.27$25.30 million$27.00 million 11/5/2019Q3 2019$0.61$0.49($0.12)$1.11$22.49 million$24.81 million 7/30/2019Q2$0.38$0.68+$0.30$1.56$21.01 million$24.99 million Ligand Pharmaceuticals Earnings - Frequently Asked Questions When is Ligand Pharmaceuticals's earnings date? Ligand Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Tuesday, August 6th, 2024. Learn more on LGND's earnings history. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of 4.250-4.750 for the period, compared to the consensus EPS estimate of 4.440. The company issued revenue guidance of $130.0 million-$142.0 million, compared to the consensus revenue estimate of $137.7 million. Did Ligand Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Ligand Pharmaceuticals (NASDAQ:LGND) reported $3.84 earnings per share (EPS) to beat the analysts' consensus estimate of $0.83 by $3.01. Learn more on analysts' earnings estimate vs. LGND's actual earnings. How can I listen to Ligand Pharmaceuticals's earnings conference call? The conference call for Ligand Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Ligand Pharmaceuticals's conference call transcript? The conference call transcript for Ligand Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Ligand Pharmaceuticals generate each year? Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded annual revenue of $131.31 million. How much profit does Ligand Pharmaceuticals generate each year? Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded net income of $52.15 million. LGND has generated $5.17 earnings per share over the last four quarters. What is Ligand Pharmaceuticals's price-to-earnings ratio? Ligand Pharmaceuticals (NASDAQ:LGND) has a trailing price-to-earnings ratio of 20.72 and a forward price-to-earnings ratio of 30.27. What is Ligand Pharmaceuticals's EPS forecast for next year? Ligand Pharmaceuticals's earnings are expected to grow from $3.54 per share to $4.60 per share in the next year, which is a 29.94% increase. More Earnings Resources from MarketBeat Related Companies: Nurix Therapeutics Earnings Praxis Precision Medicines Earnings Travere Therapeutics Earnings Arcturus Therapeutics Earnings COMPASS Pathways Earnings Shattuck Labs Earnings Ionis Pharmaceuticals Earnings Halozyme Therapeutics Earnings Exelixis Earnings Madrigal Pharmaceuticals Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Leading Healthcare Provider Stock Soars on Earnings BeatViking Therapeutics: Pharma Stock Soars on Positive EarningsEarnings Season Sell-Off: Is This Tech Giant a Buy?Pharma Leader Beats on Earnings, But Shares FallSemiconductor Giant Posts Big Earnings Beat, but Shares Stay FlatIs This Industrial Stock a Buy After Recent Earnings Boost?Consumer Staple Stock's Q2 Earnings: Key Surprises and Challenges This page (NASDAQ:LGND) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
